Publications by authors named "Anastasios Ilias"
The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn's Disease With Poor Prognostic Factors: The MODIFY Study.
Crohns Colitis 360
October 2021
Article Synopsis
- This study investigates the impact of early vs delayed treatment with adalimumab (ADL) on remission rates in Crohn's disease patients with poor prognostic factors, using data from 10 hospitals in Greece.
- Results showed that patients who started ADL within 24 months of diagnosis had a higher 26-week remission rate (60.7%) compared to those who started after 24 months (47.2%), particularly in those new to anti-tumor necrosis factor treatments.
- Overall, early treatment led to better clinical outcomes, with higher remission and response rates, especially for patients who were steroid-dependent or had additional health complications related to their condition.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) with multisystem involvement. Cases of TMA in the intestinal vasculature (intestinal TMA/iTMA) have been reported. We hypothesized that iTMA is a distinct entity from TA-TMA.
View Article and Find Full Text PDFObjective: Tamoxifen induced hepatotoxicity has not been investigated in breast cancer patients with pre-existing liver steatosis. The aim of our study was to investigate the most common predisposing factors for non-alcoholic fatty liver disease in breast cancer patients with liver steatosis, treated with adjuvant tamoxifen therapy, in order to evaluate their role in the appearance of tamoxifen induced hepatotoxicity.
Methods: Clinical and laboratory evaluation, including an oral glucose tolerance test, was done in 60 women with breast cancer and liver steatosis before the beginning of adjuvant tamoxifen treatment and every 6 months during treatment.